Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study

L. Apetoh, S. Ladoire, G. Coukos, F. Ghiringhelli, Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Annals of Oncology. ,vol. 26, pp. 1813- 1823 ,(2015) , 10.1093/ANNONC/MDV209

E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026

Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954

T Kamba, D M McDonald, Mechanisms of adverse effects of anti-VEGF therapy for cancer. British Journal of Cancer. ,vol. 96, pp. 1788- 1795 ,(2007) , 10.1038/SJ.BJC.6603813

Drew M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy Nature Reviews Cancer. ,vol. 12, pp. 252- 264 ,(2012) , 10.1038/NRC3239

Lee S. Schwartzberg, Edward J. Stepanski, Barry V. Fortner, Arthur C. Houts, Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences Supportive Care in Cancer. ,vol. 16, pp. 393- 398 ,(2008) , 10.1007/S00520-007-0329-5

David H Johnson, Louis Fehrenbacher, William F Novotny, Roy S Herbst, John J Nemunaitis, David M Jablons, Corey J Langer, Russell F DeVore III, Jacques Gaudreault, Lisa A Damico, Eric Holmgren, Fairooz Kabbinavar, Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 22, pp. 2184- 2191 ,(2004) , 10.1200/JCO.2004.11.022

Fan Zhou, Jiang-Hua Shao, Lin-Quan Wu, Xiang-Bao Yin, Xin Yu, Risk of Serious Neutropenic Events in Cancer Patients Treated with Bevacizumab: A Meta-analysis Asian Pacific Journal of Cancer Prevention. ,vol. 14, pp. 2453- 2459 ,(2013) , 10.7314/APJCP.2013.14.4.2453

M Reck, J Von Pawel, P von Zatloukal, R Ramlau, V Gorbounova, V Hirsh, N Leighl, J Mezger, V Archer, N Moore, C Manegold, BO17704 Study Group, Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Annals of Oncology. ,vol. 21, pp. 1804- 1809 ,(2010) , 10.1093/ANNONC/MDQ020

Giorgio V Scagliotti, Cornelius Kortsik, Graham G Dark, Allan Price, Christian Manegold, Rafael Rosell, Mary O'Brien, Patrick M Peterson, Daniel Castellano, Giovanni Selvaggi, Silvia Novello, Johannes Blatter, Louis Kayitalire, Lucio Crino, Luis Paz-Ares, None, Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial Clinical Cancer Research. ,vol. 11, pp. 690- 696 ,(2005)